Welcome to L’AuRa: Digital Platform for Rapid POC

L’AuRa is the result of diligent discovery, state of the art nano-science and a collaborative team penchant for uncompromising precision.

Presently no rapid human diagnostic testing system can deliver central laboratory grade high-sensitivity quantitation in a rapid mobile point of care format without sacrificing precision or quality.

LamdaGen’s L’AuRa system enables an important performance shift away from traditional analog-based central laboratory ELISA testing to a modern digital platform. L’AuRa’s adaptive sensor systems are easily integrated into remote patient monitoring systems or miniaturized mobile POC devices.

The simplicity and robust mobility of LamdaGen’s sensor technology enable advanced single-step detection systems to fulfill the unmet global need for patient-centric POC testing as defined by:

  • Rapid results
  • High analytical sensitivity with quantitative precision
  • Design simplicity and ease of use
  • Single or multiplexed targets

Beyond human diagnostics, L’AuRa’s digital sensing systems are also well suited for high impact applications in industrial or consumer-oriented food safety, companion animal and animal food stock, and certain environmental health applications – where point of use can be anywhere.

The L’Aura sensing system is economical, easy to use, scalable and easily integrated into single, multiplex and multi-panel diagnostic products. L’AuRa is also compatible with any biomarker, including low-abundance ones.

L’AuRa small benchtop optical reader and cartridge for quantitative POC diagnostics


L’AuRa enables next-generation decentralized diagnostic precision – outside the walls of the hospital

The L’AuRa digital system enables decentralized testing for earlier detection, treatment and prevention of disease. The system’s laboratory grade performance is particularly well suited for critical care settings such as ER’s, ICU’s and first responder units, as well as for POC and mobile testing in clinics, urgent care facilities, physician offices, pharmacies, mobile/field and in-home patient monitoring.

LamdaGen licenses its patented and proprietary sensor technologies on an open architecture basis to companies for integration into their existing diagnostic systems and devices, or into advanced POC or mobile/wearable products in development.

LamdaGen has optimized L’AuRa’s performance to clinical levels for many targets including:

L'AuRa for high performance, rapid and mobile POC diagnostics

To learn more email: L.AuRa@lamdagen.com



L’AuRa High Sensitivity Pathogen Detection in a Single-Step (no wash step) 15 Minute Assay
Legionella pneumophila serotype I – A bacteria causal to Legionnaires’ Disease


  • Legionella is a bacterium that can cause serious respiratory disorders. Outbreaks are considered a public health concern, since they require intensive care, hospitalization and are potentially fatal.
  • People contract Legionellosis by breathing in small airborne droplets of water containing Legionella.  Common sources associated with Legionnaires’ disease are central water systems often found in hotels, cruise ships, hospitals, schools, long-term care facilities, air conditioners and cooling towers. (1, 2)
  • Increasing global incidence and awareness has led to increased government mandated testing, driving demand for more sensitive and adaptive diagnostic solutions. To combat outbreaks, advanced technologies that improve detection sensitivity, reliability and speed are needed for better on-site testing and preventive maintenance. (2)
  • The L’AuRa Legionella assay is applicable for onsite and real-time application vs. current tests requiring days for results.
  • Dose response curve (shown right) for Legionella quantitation in a 15 minute assay format using LamdaGen’s L’AuRa digital platform.
    • Each data point represents the average of 4 repeats
    • Assay range shown is between 104 cfu/mL – 10cfu/mL
LamdaGen L'AuRa no wash step rapid Legionella assay - quantitative with high sensitivity

1. Centers for Disease Control and Prevention (2017). National Notifiable Diseases Surveillance System, 2016 Annual Tables of Infectious Disease Data. Atlanta, GA. CDC Division of Health Informatics and Surveillance. Available at: https://wonder.cdc.gov/nndss/static/2016/annual/2016-table1.html

2. Grand View Research (Jan. 2017), Legionella Testing Market Size & Forecast By Application, IVD Testing, And Trend Analysis From 2018 To 2025 —https://www.grandviewresearch.com/industry-analysis/legionella-testing-market

Zika Virus

L’AuRa High Sensitivity & Rapid Detection of Zika NS1 in a Single-Step (no wash step) 15 Minute Assay
Zika NS1- A protein indicative of acute Zika viral infection 

Zika Virus:

  • Zika is a member of the flavivirus family (including dengue, West Nile, yellow fever and chikungunya) which present with similar initial symptoms.
  • Zika infection is spread to humans by mosquitoes, there is also evidence that transmission can be human-to-human. (1)
  • There is increasing evidence that Zika can lead to the development of serious neurological disorders including microcephaly newborns of women infected during pregnancy and Guillain-Barré syndrome in infected adults. (1)
  • Rapid lateral flow NS1 assays are semi-quantitative and suffer from poor limits of detection (> 30 ng/mL). (2)
  • ELISA tests for NS1 are quantitative and have a LODs ~ 1 ng/mL, take ~3 hrs to perform, and suffer from strong cross-reactivity with the dengue serotype 3 NS1 protein. (2)
  • The L’AuRa Zika NS1 assay overcomes the issues with current tests in terms of detection limits, cross-reactivity and speed, and are ideal for POC implementation.
    • A quantitative 20 minute rapid single step (no wash step) assay
    • LOD ~ 0.5 ng/mL with a dynamic range <0.7 ng/mL to over 100 ng/mL (top image)
    • Negligable NS1 cross-reactivity with dengue serotypes 1, 2, 3 & 4, West Nile virus or yellow fever (bottom image)

1. World Health Organization, Zika Strategic Response Plan, Quarterly update, October 2016; online version accessible at https://www.who.int/emergencies/zika-virus/quarterly-update-october/en/

2. Bosch et al., Rapid antigen tests for dengue viruses serotypes and Zika virus in patient serum, Sci. Transl. Med. 9, eaan1589 (2017) and references therein.

LamdaGen L'AuRa no wash step rapid acute Zika NS1 assay - quantitative with high sensitivity LamdaGen L'AuRa no wash step rapid acute Zika NS1 assay has minimal cross-reactivity with other flavivirus NS1


L’AuRa and Precise Cortisol Quantification in a Single-Step 15 Minute Assay
A biomarker indicative of the body’s response to stress


  • In healthy humans, cortisol production follows a personal rhythm, peaking in early morning and dropping to the lowest concentration at night. In response to stress, cortisol levels rise independently of the circadian cycle.
  • Prolonged periods of irregular cortisol levels are well-evidenced to have negative impacts on mental, physical and emotional performance and well being (1, 2).
  • Dose response curve (shown right) for saliva-based cortisol quantitation in a competitive 15-minute assay format using LamdaGen’s L’AuRa digital platform.
    • Each data point represents the average of 5 repeats
    • The assay range is between 50 pg/mL – 5 ng/mL
    • The recovery yield percentages range from 92% to 110%, with an average of 101%

LamdaGen L'AuRa assay Cortisol saliva-based stress test

1. L.D. Dorn et al., Salivary cortisol reflects serum cortisol: analysis of circadian profiles, Ann Clin Biochem 44, 281-284 (2007)

2. E. Aardal & A Holm, Cortisol in saliva – reference ranges in relation to cortisol in serum, Eur J Clin Chem Clin Biochem 33(12) 81-94 (1995)